Persistent Asset Partners Ltd Decreases Stock Position in Relay Therapeutics, Inc. $RLAY
Persistent Asset Partners Ltd trimmed its holdings in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 89.8% during the second quarter, according to the company in its most recent filing with...
MarketBeat·3d ago
More News
Relay Therapeutics, Inc. $RLAY Holdings Increased by Savant Capital LLC
Savant Capital LLC lifted its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 113.7% in the second quarter, according to the company in its most recent 13F filing with the Securities...
MarketBeat·3d ago
Relay Therapeutics (NASDAQ:RLAY) Shares Up 6.1% - Still a Buy?
Relay Therapeutics (NASDAQ:RLAY) Trading 6.1% Higher - Here's What Happened...
MarketBeat·6d ago
Research Analysts Set Expectations for RLAY FY2025 Earnings
Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Equities researchers at HC Wainwright lowered their FY2025 earnings estimates for shares of Relay Therapeutics in a report issued on Monday...
MarketBeat·7d ago
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.
Relay Therapeutics (NASDAQ:RLAY - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.43) earnings per share for the quarter, missing the consensus...
MarketBeat·12d ago
Relay Therapeutics (NASDAQ:RLAY) Price Target Raised to $6.00 at Wells Fargo & Company
Wells Fargo & Company increased their price target on shares of Relay Therapeutics from $4.00 to $6.00 and gave the company an "equal weight" rating in a research report on Friday...
MarketBeat·12d ago
Relay Therapeutics, Inc. (NASDAQ:RLAY) Given Average Recommendation of "Moderate Buy" by Analysts
Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the nine research firms that are covering the firm, Marketbeat...
MarketBeat·14d ago
Wall Street Analysts Think Relay Therapeutics (RLAY) Could Surge 86.05%: Read This Before Placing a Bet
The consensus price target hints at an 86.1% upside potential for Relay Therapeutics (RLAY). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.